Medytox has increased its damages claim against Daewoong in Korean court from ₩50 billion to ₩500 billion (roughly $375 million USD) in a strain-related intellectual property dispute. The case centers on alleged misappropriation of proprietary botulinum toxin strain technology and manufacturing know-how.
Business & M&A
Medytox Boosts Daewoong Damages Claim Tenfold to ₩500 Billion
Korean botulinum toxin makers locked in escalating patent and trade secret litigation over strain technology.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Medytox escalates damages claim against Daewoong to ₩500 billion over strain technology.
This tenfold escalation reflects the stakes in the global toxin market. Medytox produces Neuronox, a botulinum toxin type A approved in Korea, Japan, and parts of Europe. Daewoong makes Nabota. Both companies are fighting for market share outside the U.S., where Allergan and Galderma have entrenched positions. Patent and trade secret litigation in Korea is notoriously protracted and unpredictable, but a ₩500 billion judgment would be material to either company's balance sheet and could reshape their international expansion timelines. U.S. practices should monitor this only if it affects supply chain stability or pricing leverage with their toxin vendor.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.